Distinct roles of GRIN2A and GRIN2B variants in neurological conditions
- PMID: 31807283
- PMCID: PMC6871362
- DOI: 10.12688/f1000research.18949.1
Distinct roles of GRIN2A and GRIN2B variants in neurological conditions
Abstract
Rapid advances in sequencing technology have led to an explosive increase in the number of genetic variants identified in patients with neurological disease and have also enabled the assembly of a robust database of variants in healthy individuals. A surprising number of variants in the GRIN genes that encode N-methyl-D-aspartate (NMDA) glutamatergic receptor subunits have been found in patients with various neuropsychiatric disorders, including autism spectrum disorders, epilepsy, intellectual disability, attention-deficit/hyperactivity disorder, and schizophrenia. This review compares and contrasts the available information describing the clinical and functional consequences of genetic variations in GRIN2A and GRIN2B. Comparison of clinical phenotypes shows that GRIN2A variants are commonly associated with an epileptic phenotype but that GRIN2B variants are commonly found in patients with neurodevelopmental disorders. These observations emphasize the distinct roles that the gene products serve in circuit function and suggest that functional analysis of GRIN2A and GRIN2B variation may provide insight into the molecular mechanisms, which will allow more accurate subclassification of clinical phenotypes. Furthermore, characterization of the pharmacological properties of variant receptors could provide the first opportunity for translational therapeutic strategies for these GRIN-related neurological and psychiatric disorders.
Keywords: ADHD; GRIN2A; GRIN2B; GluN2A; GluN2B; NMDA receptors; autism; epilepsy; intellectual disability; mutations; neurological disorder; precision medicine; psychiatric disorders; schizophrenia.
Copyright: © 2019 Myers SJ et al.
Conflict of interest statement
Competing interests: SFT is PI on a research grant from Allergan and Janssen and Emory University School of Medicine, is a member of the SAB for Sage Therapeutics, is co-founder of NeurOp Inc, and receives royalties for software. SFT and SJM are co-inventors on Emory-owned Intellectual Property that includes allosteric modulators of NMDAR function.No competing interests were disclosed.No competing interests were disclosed.
Figures

References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous